Summary
IMI’s Antimicrobial Resistance (AMR) Accelerator programme comprises several projects with the shared goal of progressing the development of new medicines to treat or even prevent resistant bacterial infections in Europe and worldwide. The COMBINE project was created to coordinate the AMR Accelerator projects and provide them with the resources they need to achieve their goals.
These include data management guidelines and an IT infrastructure to enable the collection, aggregation, storage, sharing and analysis of datasets generated by AMR Accelerator projects. COMBINE will also help to ensure that data adheres to ‘FAIR’ principles, i.e. it is findable, accessible, interoperable, and re-useable. Promoting communication among the projects is another COMBINE priority.
On the scientific front, COMBINE aims to improve the animal models used in AMR research and develop improved tools to reliably translate results in animals into results in humans. The project also aims to optimise the design and analysis of clinical trials. These tools will help all projects in the programme to deliver results that will help to accelerate the development of novel antibiotics and vaccines against AMR.
Participants
Show participants on mapEFPIA companies
- Evotec International GMBH, Hamburg, Germany
- Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
- Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
- Beam Alliance, Paris, France
- Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany
- Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München, Germany
- Statens Serum Institut, Copenhagen S, Denmark
- Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Asclepia Outsourcing Solutions, Destelbergen, Belgium
- Biocom Interrelations GMBH, Berlin, Germany
- Gritsystems As, Dragør, Denmark
| Participants | |
|---|---|
| Name | EU funding in € |
| Asclepia Outsourcing Solutions | 338 228 |
| Beam Alliance | 104 255 |
| Biocom Interrelations GMBH | 356 289 |
| Biocom Media AG (left the project) | 293 711 |
| Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel | 1 466 860 |
| Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | 800 000 |
| Gritsystems As | 800 625 |
| Statens Serum Institut | 812 500 |
| Uppsala Universitet | 3 027 532 |
| Total Cost | 8 000 000 |
Anders Karlen
Uppsala Universitet